Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2022; 10(03): E230-E231
DOI: 10.1055/a-1728-9371
Letter to the editor

Real-life practice data on colon capsule endoscopy: We need them fast!

Anastasios Koulaouzidis
1   Department of Medicine, OUH Svendborg, Sygehus, Denmark
2   Department of Clinical Research, University, of Southern Denmark (SDU), Denmark
3   Department of Social Medicine & Public Health, Pomeranian Medical University, Poland
,
Thomas Bjørsum-Meyer
4   Surgical Research Unit, Odense University Hospital, Svendborg, Denmark
,
Ervin Toth
5   Department of Gastroenterology, Skåne University Hospital, Malmö, Lund University, Sweden
› Institutsangaben
 

We read with interest the report on colon capsule endoscopy (CCE) in clinical practice: lessons from a national 5-year observational prospective cohort, by Benech et al. on behalf of the ONECC Study Group [1]. Real-life practice reports with long-term prospective follow-up, out of the scope of clinical trials, help establish a multifaceted evidence base and improve confidence in new approaches and modalities. Pending interim results of a big population-based Danish trial on CCE in colorectal cancer (CRC) screening [2], this study lays out some of the main reasons that prevent CCE from being the primary diagnostic test for the large bowel in cancer screening [3]. Interestingly, in a small, real-life, single-center cohort, using the same laxative-booster combination, we showed that even in younger patients (median age 56 years), CCE could achieve complete colonic examination in only 75 % of cases [4].

In a recent meta-analysis, we demonstrated that low completeness and adequate cleanliness rates (ACRs) torment CCE irrespective of the clinical setting (observational vs randomized clinical trials) [5]. In the same meta-analysis, we established that although polyethylene glycol (PEG) laxative and sodium phosphate (NaP) booster were the most used, they were not associated with higher completion rates or ACRs. In a recent systematic review [6], the use of CCE appeared to be a safe and effective tool for detecting CRC and polyps in a CRC screening setting. Accuracy was comparable to colonoscopy and superior to computed colonography (CTC), making CCE a good alternative to colonoscopy in CRC screening programs, although completion rates require improvement. It is important to note that no significant complication related to CCE was reported in this paper, despite a selected population with many significant comorbidities.

Benech et al. providee a practical patient management algorithm, according to colon capsule endoscopy (CCE) results obtained from the ONECC cohort. This is on par with other published proposals [7] and the realistic medicine guidance suggested by the ScotCap clinical leads collaboration [8]. CCE studies are time-consuming to read and interpret, and human errors are bound to happen [9] [10]. The application so artificial intelligence (AI) to CCE with deep learning convolutional neural network algorithms [11] could lead to automated polyp identification and/or characterisztion with improved sensitivity and reduced time demands by highlighting images with abnormalities for physician review. However, AI will only detect lesions that are already visible; therefore, future research should focus on improving bowel preparation to improve the cleanliness and completeness rate for CCE to the recommended minimum level of 90 % for optical colonoscopy [12].

Correction

Real-life practice data on colon capsule endoscopy: We need them fast! Anastasios Koulaouzidis, Thomas Bjørsum-Meyer, Ervin Toth Endoscopy International Open 2022; 10: E230–E231. DOI: 10.1055/a-1728-9371
In the above-mentioned article the authorsʼ names and affiliations were corrected. They are as follows:
Anastasios Koulaouzidis1, 2, 3, Thomas Bjørsum-Meyer4, Ervin Toth5

1 Department of Medicine, OUH Svendborg, Sygehus, Denmark
2 Department of Clinical Research, University, of Southern Denmark (SDU), Denmark
3 Department of Social Medicine & Public Health, Pomeranian Medical University, Poland
4 Surgical Research Unit, Odense University Hospital, Svendborg, Denmark
5 Department of Gastroenterology, Skåne University Hospital, Malmö, Lund University, Sweden
This was corrected in the online version on 4 April 2022.


Competing interests

Dr. Koulaouzidis is co-founder of AJM Med-i-caps; co-director of iCERV Ltd; has received consultancy fees from Jinshan Ltd, received travel support from Jinshan Ltd, Aquilant, and DrFalkPharma; has received research support in the form of a grant from ESGE/Given Imaging Ltd and in the form of material from IntroMedic/SynMed; and has received honoraria from DrFalkPharmaUK, Fering, and Jinshan. He is a member of the advisory board for DrFalkPharma UK, Tillots, and ANKON.


Corresponding author

Anastasios Koulaouzidis
Pomeranian Medical University in Szczecin
Department of Social Medicine & Public Health
ul. Rybacka 1
Szczecin 70-204
Poland   
Fax: +44-131-242-1619   

Publikationsverlauf

Artikel online veröffentlicht:
14. März 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany